Is Eli Lilly and Company Stock Underperforming the Dow?

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on neuroscience, diabetes, oncology, and immunology. The company markets a broad range of human pharmaceuticals across the U.S., Europe, China, Japan, and other international markets.

Companies valued over $200 billion are generally described as “mega-cap” stocks, and Eli Lilly fits right into that category. Lilly has expanded its pipeline and portfolio through strategic acquisitions, including ImClone Systems, ICOS Corporation, Loxo Oncology, and Dermira, as well as through collaborations with Incyte, Boehringer Ingelheim, Roche/Genentech, and others.